Image of Doudna with computer model of CRISPR

University of California awarded 15th U.S. CRISPR-Cas9 patent

The U.S. Patent and Trademark Office (USPTO) today granted the University of California (UC) and its partners, the University of Vienna and Emmanuelle Charpentier, a new CRISPR-Cas9 patent, bringing the team’s continually expanding patent portfolio to 15.

U.S. Patent 10,421,980 covers compositions of certain DNA-targeting RNAs that contain RNA duplexes of defined lengths that hybridize with Cas9 and target a desired DNA sequence. The patent also covers methods of targeting and binding a target DNA, modifying a target DNA, or modulating transcription from a target DNA wherein the method comprises contacting a target DNA with a complex that includes a Cas9 protein and a DNA-targeting RNA.

In the coming months, based on applications allowed by the USPTO, UC’s CRISPR-Cas9 patent portfolio will increase to 18. Together, these patents cover compositions and methods for CRISPR-Cas9 gene-editing, including targeting and editing genes and modulating transcription in any setting, such as within plant, animal and human cells.




UC Berkeley



This is a unique website which will require a more modern browser to work!

Please upgrade today!